Objective: To determine whether people with sporadic vestibular schwannoma (VS) who take aspirin for unrelated medical reasons exhibit less tumor growth than nonaspirin users. We previously demonstrated the efficacy of salicylates in inhibiting VS growth in vitro, corroborating the results of our retrospective clinical study, which found halted VS growth (based on linear tumor measurements) in aspirin users. The current study evaluates this association using more accurate tumor volumetric measurements, and quantifies the degree of frequency-specific, VS-induced hearing loss. Study Design: Retrospective analysis. Setting: Tertiary care hospital. Patients: Diagnosed with VS between 1980 and 2012, followed by serial magnetic resonance imaging for at least 1 year. Main Outcome Measures: Patient history of aspirin intake; change in VS volume over time of observation; frequencyspecific, VS-induced audiometric threshold shifts.
Vestibular schwannoma (VS) is one of the most common nonmalignant intracranial nerve sheath tumors (1) . VS accounts for 8% of all intracranial tumors and 80% of cerebellopontine angle (CPA) tumors. VS typically arises from Schwann cells of the superior and inferior vestibular nerves that are part of the VIII cranial nerve. The tumor forms sporadically and unilaterally in 95% of patients (incidence 1:10,000) (2) or in association with neurofibromatosis type 2 whose hallmark is bilateral VSs (incidence 1:33,000) (3). VS incidence has increased over the years, presumably because of improved imaging techniques and diagnostic awareness among clinicians (4, 5) . Contrast-enhanced magnetic resonance imaging (MRI) of the brain is currently the gold standard for diagnosing VS. The widespread use of brain MRI has enabled discovery of incidental and asymptomatic VSs (5-7). Nevertheless, many people with small VS may remain undiagnosed, making it difficult to determine the prevalence of VS in the general population. When serially sectioned temporal bones were routinely examined in 521 individuals, the histologic incidence of VS was 1:100 (8) , suggesting that VS is much more common than clinically recognized.
Sensorineural hearing loss is the most commonly presenting sign of VS, occurring in 95% of patients (9) . Other common symptoms include tinnitus and dizziness. As VSs grow, they can cause additional cranial nerve neuropathies, hydrocephalus, and even death from brainstem compression (9, 10) . Current management options for growing or symptomatic VSs are essentially limited to stereotactic radiation therapy and surgical resection via craniotomy. Both of these options involve significant potential risks, including deafness and facial paralysis. Identifying effective pharmacotherapies for VS is a major unmet medical need as no drug is FDAapproved to treat VS. The only drug showing activity against VS in clinical trials is bevacizumab, which inhibits vascular endothelial growth factor. Bevacizumab decreases tumor growth or improves hearing, typically temporarily, in 54% of patients (11) . However, long-term use of this expensive drug is associated with severe side effects, including renal failure (12) . New and well-tolerated therapies against VSs are therefore urgently needed.
To address this need, we have been investigating salicylates, a class of nonsteroidal antiinflammatory drugs that are well tolerated and inexpensive. We have focused specifically on aspirin because it modifies the COX-2's enzymatic activity (13) and COX-2 expression in VS correlates with a high tumor proliferation rate (14) . Moreover, aspirin provides chemoprevention for multiple human malignancies, including colon, gastric, breast, and prostate cancer (15) (16) (17) (18) by modulating COX-2 activity. Our retrospective longitudinal clinical study of VS patients who underwent serial MRI scanning revealed that patients taking aspirin for unrelated medical reasons were less likely to have VS growth than patients not taking aspirin (19) . This study, based on linear VS measurements, inspired a mechanistic study with primary human VS cells (20) . In the latter study we found that COX-2 is aberrantly expressed in human VSs and their derived primary VS cultures relative to control human nerve specimens and their derived primary Schwann cells (SCs). Primary VS culture proliferation rate correlated with their secretion of prostaglandin E2, the downstream enzymatic product of COX-2. Aspirin was cytostatic against cultured VS cells and did not affect healthy SCs (20) .
Moreover, our bioinformatic network analysis of all genes reported to be differentially expressed in human VS revealed a pro-inflammatory transcription factor nuclear factor-kappa B (NF-kB) as a central molecule in VS pathobiology (21) . This finding was validated by demonstrating aberrant activation of the canonical NFkB complex in human VSs and derived VS cultures relative to control nerves and SCs, and by proving cytotoxicity when directly targeting NF-kB in VS cells (21) . Importantly, aspirin is known to inhibit NF-kB activation (22, 23) .
Motivated by our preclinical (20) and clinical (19) data implicating aspirin's potential to prevent VS growth, we undertook the current study to define the correlation between aspirin intake and VS volume. Volumetric tumor measurements are more precise than linear tumor measurements (24) (25) (26) (27) based on Response Evaluation Criteria in Solid Tumors (RECIST) (28) . The volumetric analysis reaffirmed the results of our linear analysis, suggesting that aspirin may inhibit VS growth.
METHODS

Patient Cohort
The study included patients diagnosed with sporadic VS at Massachusetts Eye and Ear Infirmary (MEEI) from January 1, 1980 to April 1, 2012. The final patient population included 86 of our originally described cohort of 347 patients followed by serial MRI (19) for at least 1 year; this subset of patients had all sequential scans available for 3D-segmented volumetric analysis. Patients were grouped into ''aspirin users'' and ''nonusers'' of aspirin. Aspirin users had documented history of aspirin intake and at least one comorbidity that warranted longterm aspirin use or met the age criterion for aspirin prophylaxis against myocardial infarction (age 45 or older in men) or stroke (age 55 or older in women) (29) . The study was approved by the institutional review board (HSC protocol number: 12-036H, P.I.: K.M.S).
Quantifying Tumor Volume
Segmented 3D volumetric analysis of VS was performed for each patient on axial contrast-enhanced T1-weighted magnetic resonance images using a Voxar unit (Toshiba Medical Visualization Systems, Edinburgh, UK) (30) . For each study, the tumor was manually outlined in the axial plane on every third sequential section. A computerized compilation of the measured slice's volume and an assessment of total tumor volume were used to create a segmented volumetric model (27) . Tumor volumes were expressed in cubic centimeters (cc). The first of the serial MRI scans was defined as baseline. In our original study (19) investigating changes in VS's single linear dimension on serial MRI scans, tumors were categorized as growing if the increase in size was greater than 0 cm, and not growing if they were stable or shrinking. The criterion for tumor growth was redefined for the present study because of the well-documented error associated with tumor volume remeasurement (24, 26, (31) (32) (33) (34) (35) and up to 50% remeasurement variability in very small tumors (volumes less than 0.05 cc). Therefore, for tumors whose original volume was >0.05 cm, we defined tumor growth as >20% positive change in volume from the first MRI scan. ''No-growth'' was defined as any change in tumor volume <20%, including tumor shrinkage, for tumors whose original volume was !0.05 cc and any change in tumor volume for tumors whose original volume was less than 0.05 cc (n ¼ 3 aspirin users and n ¼ 2 nonusers). All measurements were made using the same algorithm and computer system by one experienced investigator (C.K.K.) who was blinded to aspirin use. The categorical classification of growth versus no growth was used because VS growth rates varied substantially among tumors.
Statistical Analysis
STATA (version 12.1, StataCorp, College Station, TX) was used for data analysis.
Fisher's exact test was used to compare the difference in proportion of VS demonstrating growth versus no growth between aspirin users and nonusers and to calculate the odds ratio (OR) and the corresponding 95% confidence interval (CI); p <0.05 was considered significant. Multiple logistic regression was used to determine if age and sex were potential confounders. Using an independent sample t test (with p <0.05 considered significant), aspirin users, nonusers, and age-adjusted nonusers were compared with regard to tumor volume at the time of the first MRI scan (null hypothesis H 0 : mean tumor volumes are equal).
Audiometric Analysis
Audiometric thresholds were obtained at 250, 500, 1000, 2000, 4000, and 8000 Hz using the standard protocol (36) . To quantify the degree of VS-induced hearing loss, the difference in audiometric thresholds (in dB) between the ear ipsilateral to the VS and the contralateral ear was calculated for each frequency and each patient. Differences between aspirin users and nonusers were compared using t test at every frequency. Benjamini-Hochberg correction for multiple hypotheses was applied to generated p values and Benjamini-Hochberg corrected p values 0.05 were considered significant. VS-induced thresholds shifts across frequencies were analyzed using analysis of variance (ANOVA).
RESULTS
Of the 81 aspirin users and 266 nonusers with serial MRI scans originally identified in our linear study of VS growth (19) , scans from a total of 86 patients followed for at least 1 year were available for 3D volumetric analysis (Table 1 ). Of the 86 available patients for the study, 25 were identified as aspirin users and 61 as nonusers. Among the aspirin users, 11 patients took 81 mg (baby strength) daily and 14 patients did not have the aspirin dose specified; the dose is assumed to be 81 or 325 mg daily based on the common medical usage. There was no mention of high-dose aspirin use in the medical records (19) . Cardiovascular disease was the most documented associated comorbidity, reported in 18 patients; seven patients had no documented associated comorbidity, except age which qualified them for aspirin prophylaxis. VS growth was noted in 44 patients (51%), 8 (18%) of whom were aspirin users (Table 1) . Forty-two patients (49%) showed no tumor growth; 17 (40%) were aspirin users. The difference in these categorical variables, i.e., VS growth versus no growth between aspirin users and nonusers was statistically significant ( p ¼ 0.03; OR: 0.32; 95% CI; 0.11-0.91; Table 2 ) and not confounded by age ( p ¼ 0.4) or sex ( p ¼ 0.26).
Because VS growth rates can be inversely correlated with age (37), we performed an age-adjustment among the nonusers by selecting the nonusers whose ages closely matched the age of aspirin users. The average age of aspirin users (67.2 yr) was significantly different ( p ¼ 0.02) from the average age of nonusers (60.4 yr), but not significantly different from the average age for age-adjusted nonusers (62.7 yr, p ¼ 0.08, Fig. 1A ). Sex distribution within and across groups is shown in Figure 1B . There were more women among the nonusers and more men among aspirin users, consistent with the reports that women are less likely to take aspirin regularly than men (38) . The MRI follow-up time ranged from 13 to 132 months, with the mean AE standard error of the mean being 4.5 AE 0.3 years for nonusers, 4.4 AE 0.3 years for age-adjusted nonusers and 4.7 AE 0.5 years for aspirin users (Fig. 1C) . The average tumor volume (cc) at the time of the first MRI, expressed as mean AE standard error of the mean, was 0.83 AE 0.18, 0.9 AE 0.19, and 0.77 AE 0.25 for nonusers, age-adjusted nonusers, and aspirin users, respectively. This trend for smaller tumor volume among the aspirin users did not meet our criterion for significance.
The degree of VS-induced hearing loss was quantified by calculating the audiometric threshold shift between the ear ipsilateral to the VS and the contralateral ear for patients with available audiograms (Fig. 2) . The initial audiogram, at the time of VS diagnosis, and the final available audiogram were analyzed. The average VSinduced threshold shift between aspirin users (n ¼ 17) and nonusers (n ¼ 40) was not statistically significant at any frequency on initial and final audiograms after applying Benjamini-Hochberg correction for multiple comparisons. The observed trend for larger thresholds Age adjustment was performed by eliminating patients from the nonusers so that the aspirin users and age-adjusted nonusers are not statistically significant in age.
MRI indicates magnetic resonance imaging. (39, 40) .
DISCUSSION
We used 3D volumetric analysis to reaffirm the inverse association between aspirin intake and VS growth that we had previously observed using linear analysis (19) . Previous studies have established that 3D volumetric analysis is superior to linear analysis for estimating tumor size and growth (24) (25) (26) (27) .
Although VS growth rate among aspirin users in our population was higher than VS growth rates reported in other studies, others did not specifically classify patients based on aspirin use. In a series involving 114 patients, Fayad et al. (41) reported 38% growth rate based on linear tumor measurements. In a smaller study involving 15 patients, Niemczyk et al. (24) reported 43% growth rate in unilateral VSs when using volumetric analysis. Volumetric tumor analysis is known to identify higher growth rates than linear analysis: when analyzing 24 unilateral VSs, Walz et al. (27) identified progression in 75% more patients with segmented volumetric analysis than with maximum linear dimension measurement. Because VSs assume complex configurations, linear measurements can inaccurately estimate tumor volume and growth compared with volumetric analysis (27) . Taken together, our results motivate future measurements of volumetric tumor growth in large cohorts of VS patients with carefully documented intake of antiinflammatory medications. Although information regarding aspirin use patterns is incomplete in our study, it is likely that patients took 81 or 325 mg daily chronically and not only occasionally. Our in vitro study with primary human VS cells showed a significant reduction in VS cell proliferation when salicylate levels of 3.3 mg/dL were measured in the media of cells treated with 5 mM aspirin (20) . To reach similar salicylate concentrations in serum, a daily dose of about 800 mg aspirin would be needed (42) . This dose is well below the range of salicylate toxicity, which starts to become apparent when serum salicylate levels exceed 25 mg/dL (43) . However, aspirin concentrations that affect cultured VS cells cannot be directly scaled to predict concentrations required to achieve a therapeutic effect with systemic administration. In a study investigating aspirin's role in preventing colorectal cancer, daily aspirin use at any dose was found to be effective (44) . Specifically, aspirin treatment at a dose ranging from 75 to 1,200 mg/day was associated with a 21% lower risk of death from cancer, and the benefit was only apparent after 5 years of follow-up (44) . The median duration of follow-up in our cohort was about 4 years. However, reduced breast cancer risk has been reported with aspirin usage as infrequent as once per week for 6 months or longer (16) .
Our finding that VS-induced audiometric threshold shifts were the largest at high frequencies is consistent with reports that high-frequency sensorineural hearing loss is the most common type VS-induced hearing loss (40, (45) (46) (47) . Specifically, VS-induced high-frequency hearing loss is the dominant pattern in Danish (40), Egyptian (46) , Turkish (45) , and Korean (47) patients. The preponderance of high-frequency sensorineural hearing loss is thought to reflect mechanical compression of the tonotopically organized cochlear nerve by VS (48, 49) . However, audiometric threshold shifts due to sporadic VS do not correlate with the radiographic tumor size or tumor extent within the internal auditory canal (50, 51) , suggesting that hearing loss due to VS is multifactorial (52) . We have recently demonstrated that VS secretions can cause direct cochlear damage (53, 54) , and that tumor necrosis factor alpha (TNFa) is an ototoxic molecule in VS secretions (53) . Interestingly, TNFa induces NF-kB activation, while aspirin inhibits it (22, 23) .
Our current and previous (19, 20) data motivate a prospective, randomized, placebo-controlled phase II trial of aspirin for VS treatment. Such a clinical trial would be an improvement over previous trials in terms of safety, treatment cost, and potential for widespread patient applicability. Previous clinical trials have often focused on expensive drugs and invasive procedures, which placed a heavy burden of care on both the provider and the patient. Our overarching objective has been to identify inexpensive drugs with lesser side effects than those caused by drugs that have been tested in clinical trials for VS thus far. Cytostatic drugs can be therapeutic without being cytotoxic because VSs are nonmalignant. Indeed, there has been a growing trend in simply observing nongrowing VSs (55), reserving surgery and radiation therapy for growing and symptomatic tumors. Our data suggests that aspirin may represent a noninvasive pharmacological approach to treatment that promises to slow and/or stop VS tumor growth. At best aspirin may prevent the need for surgery or radiation therapy; in the least aspirin may allow the patient and clinician more time to make decisions regarding timing of intervention. Previous research has indicated that inflammation may play a key role in VS development and progression, and histological analyses of resected tumors have found chronic inflammation, sheets of macrophages, nuclear atypia, and scarring (56) . As chronic inflammation is a well-established trigger for tumor development (57) the systemic reduction of inflammation may provide potent and persistent benefits for the delaying tumor growth in VSs.
Limitations of our retrospective study include a relatively small sample size due to the inability to access serial MRI scans performed at outside institutions and reliance on self-reported aspirin use when precise dosing information was not available in medical records. By design, the study is correlative, not causative. It is possible that the overall health of patients on aspirin may be different from nonusers, which may independently affect VS growth. The role of cerebrovascular disease in VS progression has not been studied. Retrospective reporting of medication use is subject to error, particularly underreporting. However, recall bias is unlikely to explain our results because people with growing VSs would have to underreport usage more than people with stable VSs (19); patients with growing tumors are more likely to seek health care and provide detailed medical information. Careful assessment of all potential confounders will be required in a future prospective clinical trial to determine whether there is a role for aspirin in VS treatment.
CONCLUSION
Our findings, which align with the results of our original clinical study (19) , with mechanistic studies in vitro (20) , and with the known presence of pathologic immune response in VS (21) , suggest a potential therapeutic role for aspirin in VS. A prospective, appropriately powered clinical study is needed to determine whether nonsteroidal antiinflammatory medications such as aspirin can prevent VS growth. The preponderance of VS-induced high-frequency sensorineural hearing loss in our population is consistent with that observed in other populations.
